Precision BioSciences Reports Full-Year Loss, Secures Cash Runway to 2028 Amidst Major Dilutive Offering & Key Clinical Progress

summarizeSummary

Precision BioSciences reported a significant net loss for 2025 but bolstered its liquidity with a substantial dilutive public offering and ATM sales, extending its cash runway through 2028. The company also advanced its PBGENE-DMD program with multiple FDA designations and IND clearance, while a major collaboration with Novartis was terminated.

check_boxKey Events

• Significant Net Loss and Revenue Decline in 2025

  The company reported a net loss of $(45.7) million for the year ended December 31, 2025, a significant decrease from a net income of $7.17 million in 2024. Revenue also declined to $34.3 million in 2025 from $68.7 million in 2024.

• Substantial Capital Raise and Extended Cash Runway

  Precision BioSciences raised approximately $75.0 million in gross proceeds from a public offering in November 2025 (issuing 10,815,000 common shares and 5,407,500 warrants) and an additional $23.9 million from its At-The-Market (ATM) facility. These capital raises, while highly dilutive, increased cash and cash equivalents to $110.8 million and extended the company's cash runway through 2028.

• Key Clinical Program Advances with Multiple FDA Designations

  The PBGENE-DMD program for Duchenne muscular dystrophy received IND clearance from the FDA in February 2026, enabling the initiation of its Phase 1/2 FUNCTION-DMD clinical trial. It also secured Rare Pediatric Disease, Orphan Drug, and Fast-Track designations, indicating significant regulatory support and potential for expedited review.

• Novartis Collaboration Terminated; Other Partnerships Yield Milestones

  Novartis Pharma AG terminated its collaboration and license agreement with Precision BioSciences, effective January 30, 2026, ending future milestone and royalty payments from that partnership. Conversely, the company received a $7.5 million clinical milestone payment from TG Therapeutics and an $8.0 million milestone payment from Imugene.

auto_awesomeAnalysis

Precision BioSciences reported a significant net loss for 2025 and a decline in revenue, reflecting the challenges of a clinical-stage biotech. However, the company successfully executed a substantial public offering and utilized an At-The-Market (ATM) facility in 2025, raising approximately $99 million in gross proceeds. This capital infusion, while highly dilutive to existing shareholders, has extended the company's cash runway through 2028, a critical factor for continued operations and pipeline development. The termination of the collaboration with Novartis Pharma AG is a notable setback, but this is partially offset by new milestone payments from TG Therapeutics and Imugene. Clinically, the PBGENE-DMD program achieved significant milestones, including IND clearance and multiple expedited FDA designations (Fast-Track, Orphan Drug, Rare Pediatric Disease), with initial clinical data anticipated by year-end 2026. The disclosure of executive severance agreements with an escrow for potential 'Restructuring Events' (including bankruptcy or liquidation) or 'Change in Control' is a highly unusual and material detail, indicating management's proactive, albeit cautious, approach to potential future corporate scenarios.